NEUROLOGY AND NEUROBIOLOGY VOLUME 8B



CATECHOLAMINES Part B: Neuropharmacology and Central Nervous System-Theoretical Aspects

Editors
Earl Usdin
Arvid Carlsson
Annica Dahlström
Jörgen Engel

Alan R. Liss, Inc., New York

CATECHOLAMINES

Part B: Neuropharmacology and Central Nervous System—Theoretical Aspects

Proceedings of the Fifth International Catecholamine Symposium, held in Göteborg, Sweden, June 12–16, 1983

Editors

Earl Usdin

Department of Psychiatry and Human Behavior
California College of Medicine
University of California, Irvine
Irvine, California

Arvid Carlsson

Department of Pharmacology
University of Göteborg
Göteborg, Sweden

Annica Dahlström

Institute of Neurobiology
University of Göteborg
Göteborg, Sweden

Jörgen Engel

Department of Pharmacology
University of Göteborg
Göteborg, Sweden

ALAN R. LISS, INC., NEW YORK

Address all Inquiries to the Publisher
Alan R. Liss, Inc., 150 Fifth Avenue, New York, NY 10011

Printed in the United States of America.

Library of Congress Cataloging in Publication Data

International Catecholamine Symposium (5th : 1983 : Göteborg, Sweden)
Catecholamines : proceedings of the Fifth International Catecholamine Symposium, Held in Göteborg, Sweden, June 12–16, 1983.
Includes bibliographies and indexes.
Contents: pt. A. Basic and peripheral mechanisms–pt. B. Neuropharmacology and central nervous system–theoretical aspects–pt. C. Neuropharmacology and central nervous system–therapeutic aspects.
1. Catecholamines–Congresses. 2. Adrenergic mechanisms–Congresses. 3. Catecholamines–Therapeutic use–Congresses. 4. Neuropharmacology–Congresses. I. Usdin, Earl. II. Title. [DNLM: 1. Catecholamines–Congresses. WI NE337B v.8 / WK 725 I59 1983c]
QP801.C3315 1983 615'.78 84-3967
Part A: ISBN 0-8451-2707-1
Part B: ISBN 0-8451-2708-X
Part C: ISBN 0-8451-2709-8
Three-Volume Set: ISBN 0-8451-2798-5

CATECHOLAMINES

Part B: Neuropharmacology and Central Nervous System—Theoretical Aspects

Neurology and Neurobiology

Volume 1
Cytochemical Methods in Neuroanatomy
Victoria Chan-Palay and Sanford L. Palay, *Editors*

Volume 2
Basic Mechanisms of Neuronal Hyperexcitability
Herbert H. Jasper and Nico M. van Gelder, *Editors*

Volume 3
Anorexia Nervosa: Recent Developments in Research
Padraig L. Darby, Paul E. Garfinkel, David M. Garner, and Donald V. Coscina, *Editors*

Volume 4
Clinical and Biological Aspects of Peripheral Nerve Diseases
Leontino Battistin, George A. Hashim, and Abel Lajtha, *Editors*

Volume 5
The Physiology of Excitable Cells
Alan D. Grinnell and William J. Moody, Jr., *Editors*

Volume 6
Developing and Regenerating Vertebrate Nervous Systems
Penelope W. Coates, Roger R. Markwald, and Alexander D. Kenny, *Editors*

Volume 7
Glutamine, Glutamate, and GABA in the Central Nervous System
Leif Hertz, Elling Kvamme, Edith G. McGeer, and Arne Schousboe, *Editors*

Volume 8
Catecholamines
Earl Usdin, Arvid Carlsson, Annica Dahlström, and Jörgen Engel, *Editors*
Published in three volumes:
Part A: Basic and Peripheral Mechanisms
Part B: Neuropharmacology and Central Nervous System—Theoretical Aspects
Part C: Neuropharmacology and Central Nervous System—Therapeutic Aspects

Contributors

G.K. Aghajanian, Departments of Psychiatry and Pharmacology, Yale University School of Medicine, New Haven, CT 06508 **[85]**

Luigi F. Agnati, Department of Human Physiology and Endocrinology, University of Modena, I-41100 Modena, Italy **[191,441]**

Ture Ålander, Department of Medical Pharmacology, Box 573, Biomedicum, S-751 23 Uppsala, Sweden **[19]**

Harvey J. Altman, Lafayette Clinic, Detroit, MI 48207 **[309]**

Nils-Erik Andén, Department of Medical Pharmacology, Box 573, Biomedicum, S-751 23 Uppsala, Sweden **[19]**

Kurt Andersson, Department of Histology, Karolinska Institute, S-104 01 Stockholm, Sweden **[441]**

S. Arbilla, LERS, 58 Rue de la Glaciere, F-75012 Paris, France **[135]**

T. Archer, Department of Pharmacology, Astra Läkemedel AB, Section AFP, S-151 85 Södertälje, Sweden **[285]**

G. Aston-Jones, Department of Psychology, SUNY-Binghamton, Binghamton, NY 13901 **[159]**

David Astrachan, Department of Psychiatry, Yale University School of Medicine and the Connecticut Mental Health Center, New Haven, CT 06508 **[245]**

J. Axelrod, Section on Pharmacology, Laboratory of Clinical Science, National Institute of Mental Health, Bethesda, MD 20205 **[419]**

Michael J. Bannon, MRC Neurochemical Pharmacology Unit, Medical Research Council Center, Hills Road, Cambridge CB2 2GH, UK **[25]**

M.L. Barbaccia, Department of Pharmacology and Pharmacognosy, University of Milan, I-20129 Milano, Italy **[141]**

M.D. Baring, Experimental Therapeutics Branch, National Institute of Neurological and Communicative Disorders and Stroke, Bethesda, MD 20205 **[343]**

Nino Battistini, Department of Human Physiology, University of Modena, I-41100 Modena, Italy **[191]**

Fabio Benfenati, Department of Human Physiology, University of Modena, I-41100 Modena, Italy **[191,441]**

Melvin L. Billingsley, Section on Biochemical Pharmacology, NHLBI, NIH, Bethesda, MD 20205 **[37]**

G. Blanc, Groupe NB, INSERM U. 114, Collège de France, F-75231 Paris cedex 5, France **[103]**

F.E. Bloom, The Salk Institute Alcohol Research Center, La Jolla, CA 92037 **[159]**

Joël Bockaert, Centre CNRS-INSERM de Pharmacologie–Endocrinologie, F-34100 Montpellier, France **[93]**

Stefan Borg, Department of Psychiatry, St. Göran's Hospital, S-112 81 Stockholm, Sweden **[153]**

Benjamin S. Bunney, Departments of Pharmacology and Psychiatry, Yale University School of Medicine, New Haven, CT 06510 **[25,313,315,323,369]**

Edward B. Bunney, Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06510 **[25]**

Laura Calza, Department of Human Physiology, University of Modena, I-41100 Modena, Italy **[441]**

Massimo Camurri, Department of Human Physiology, University of Modena, I-41100 Modena, Italy **[191,441]**

The numbers in brackets are opening page numbers of each author's article.

A complete list of conference participants appears in Catecholamines, Part C.

Louis A. Chiodo, Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06510 **[25,369]**

Randall Commissaris, Department of Psychiatry, Yale University School of Medicine and the Connecticut Mental Health Center, New Haven, CT 06708 **[245]**

J. Costentin, Laboratoire de Pharmacodynamie et Physiologie, U.E.R. de Medecine et Pharmacie, B.P. 97, F-76800 St. Etienne-du-Rouvray, France **[59]**

J. Côté, MRC Group in Molecular Endocrinology, Le Centre Hospitalier de l'Université Laval, Quebec G1V 4G2, Canada **[409]**

Floy L. Crutchfield, Medical Research Service, VA Medical Center and The Medical College of Pennsylvania, Philadelphia, PA 19104 **[425]**

Gerald Curzon, Institute of Neurology, 33 Johns Mews, London WC1N 2NS,UK **[471]**

Michael Davis, Department of Psychiatry, Yale University, New Haven, CT 06508 **[245]**

M. Delandre, Unité de Neurobiologie, Centre Paul Broca de l'INSERM, F-75014 Paris, France **[59]**

Keith T. Demarest, Department of Pharmacology and Toxicology, Michigan State University, East Lansing, MI 48824 **[451]**

J. Demling, Reproduktionsbiologie, Max Planck Institute, D-3400 Göttingen, FRG **[463]**

Mary B. Dratman, Veterans Administration Medical Center, Philadelphia, PA 19104 **[425]**

Alain Enjalbert, Unité de Neuroendocrinologie, Centre Paul Broca de l'INSERM, F-75014 Paris, France **[93]**

Barry J. Everitt, Department of Histology, Karolinska Institute, S-104 01 Stockholm, Sweden **[231]**

F. Fadda, Institute of Physiology, University of Cagliari, I-09100 Cagliari, Italy **[13]**

B. Fanni, Institute of Pharmacology, University of Cagliari, I-09100 Cagliari, Italy **[353]**

S.L. Foote, The Salk Institute Alcohol Research Center, La Jolla, CA 92037 **[159]**

Abraham L. Frankhuyzen, Department of Pharmacology, Free University, Medical Faculty, NL-1081 BT Amsterdam, The Netherlands **[47]**

William Freed, Department of Health and Human Services, St. Elizabeth's Hospital, Washington, DC 20032 **[333]**

E. Fuchs, Deutsches Primatenzentrum, BEI MPI Fassberg, D-3400 Göttingen, FRG **[463]**

Sara Fuchs, Department of Chemical Immunology, The Weizmann Institute of Science, Rehovot 76100, Israel **[137]**

Kjell Fuxe, Department of Histology, Karolinska Institute, S-104 01 Stockholm, Sweden **[191,441]**

Dorothy Gallager, Department of Psychiatry, Yale University, New Haven, CT 06510 **[245]**

Matthew P. Galloway, Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06510 **[37]**

D.C. German, Department of Physiology, University of Texas Health Science Center, Dallas, TX 75235 **[135]**

G.L. Gessa, Institute of Pharmacology, University of Cagliari, I-09100 Cagliari, Italy **[13,353]**

Luciana Giardino, Department of Human Physiology, University of Modena, I-41100 Modena, Italy **[441]**

J. Glowinski, Unité de Neuropharmacologie Biochemie, Collège de France, F-75231 Paris, France **[103]**

Menek Goldstein, Department of Psychiatry, New York University Medical Center, New York, NY 10016 **[231,441]**

Janice T. Gordon, Medical Research Service, VA Medical Center and The Medical College of Pennsylvania, Philadelphia, PA 19104 **[425]**

Maria Grabowska-Andén, Department of Medical Pharmacology, Box 573, Biomedicum, S-751 23 Uppsala, Sweden **[19]**

Anthony A. Grace, Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06510 **[25,323]**

M. Graf, Reproduktionsbiologie, Max Planck Institute, D-3400 Göttingen, FRG **[463]**

D.L. Gruol, The Salk Institute Alcohol Research Center, La Jolla, CA 92037 **[131,159]**

C. Gulat, Laboratoire de Physiologie, Faculté de Pharmacie, F-75005 Paris, France **[59]**

N.C. Harris, Department of Physiology and Pharmacology, University of Southampton, Southampton S09 3TU, UK **[403]**

Thomas G. Heffner, Pharmaceutical Research Division, Warner-Lambert/Parke-Davis, Ann Arbor, MI 48105 **[275]**

S. Heisler, Laboratory of Cell Biology, National Institute of Mental Health, Bethesda, MD 20205 **[419]**

Barry J. Hoffer, Department of Pharmacology, University of Colorado Medical Center, Denver, CO 80262 **[219,333]**

Tomas Hökfelt, Karolinska Institute, Department of Histology, S-104 01 Stockholm, Sweden **[175,179,191,231]**

Robert E. Hruska, Department of Biochemical Pharmacology, State University of New York, Buffalo, NY 14260 **[123]**

Barry L. Jacobs, Department of Psychology, Princeton University, Princeton, NJ 08544 **[393]**

Peter W. Kalivas, Department of Pharmacology, Louisiana State University School of Medicine, New Orleans, LA 70112 **[199]**

H. Keck, Reproduktionsbiologie, Max Planck Institute, D-3400 Göttingen, FRG **[463]**

John Kehne, Department of Psychiatry, Yale University School of Medicine and the Connecticut Mental Health Center, New Haven, CT 06508 **[245]**

K. Kiianmaa, Research Laboratories of the Finnish State Alcohol Company (Alko Ltd), SF-00101 Helsinki 10, Finland **[145]**

M. Knight, Experimental Therapeutics Branch, National Institute of Neurological and Communicative Disorders and Stroke, Bethesda, MD 20205 **[343]**

Hans Kvande, Department of Psychiatry, Karolinska Institute, St. Göran's Hospital, S-112 81 Stockholm, Sweden **[153]**

F. Labrie, MRC Group in Molecular Endocrinology, Le Centre Hospitalier de l'Université Laval, Québec G1V 4G2, Canada **[409]**

A. Laffite, Laboratoire de Physiologie, Faculté de Pharmacie, F-75005 Paris, France **[59]**

P. Laibe, Laboratoire de Pharmacochimie Moléculaire, Centre de Neurochimie, F-67000 Strasbourg, France **[59]**

R. Lamberts, Reproduktionsbiologie, Max Planck Institute, D-3400 Göttingen, FRG **[463]**

T.H. Lanthorn, Experimental Therapeutics Branch, National Institute of Neurological and Communicative Disorders and Stroke, Bethesda, MD 20205 **[343]**

G. Lefevre, MRC Group in Molecular Endocrinology, Le Centre Hospitalier de l'Universite Laval, Quebec G1V 4G2, Canada **[409]**

S.F. Leibowitz, The Rockefeller University, New York, NY 10021 **[473]**

M. Le Moal, Laboratoire de Neurobiologie des Comportements, Université de Bordeaux II, F-33076 Bordeaux cedex, France **[293]**

T. Lewander, Research Department, Ulleråkers Sjukhus, S-75017 Uppsala, Sweden **[169]**

Bo Liljenberg, Department of Medical Pharmacology, Box 573, Biomedicum, S-751 23 Uppsala, Sweden **[19]**

Silvana Lindgren, Department of Medical Pharmacology, Box 573, Biomedicum, S-751 23 Uppsala, Sweden **[19]**

L. Lucchi, Department of Pharmacology and Pharmacognosy, University of Milan, I-20129 Milano, Italy **[141]**

J.M. Lundberg, Department of Pharmacology, Karolinska Institute, S-10401 Stockholm, Sweden **[179]**

A. Mann, Laboratoire de Pharmacochimie Moleculaire, Centre de Neurochimie, F-67000 Strasbourg, France **[59]**

T. Mansky, Reproduktionsbiologie, Max Planck Institute, D-3400 Göttingen, FRG **[463]**

M. Marcou, Institute of Pharmacology, University of Cagliari, I-09100 Cagliari, Italy **[13]**

M.P. Martres, Unité de Neurobiologie, Centre Paul Broca de l'INSERM F-75014 Paris, France **[59]**

G. Mereu, Institute of Pharmacology, University of Cagliari, I-09100 Cagliari, Italy **[353]**

H. Meunier, MRC Group in Molecular Endocrinology, Le Centre Hospitalier de l'Université Laval, Quebec G1V 4G2, Canada **[409]**

E. Mezey, Laboratory of Cell Biology, National Institute of Mental Health, Bethesda, MD 20205 **[419]**

Kenneth E. Moore, Department of Pharmacology and Toxicology, Michigan State University, East Lansing, MI 48824 **[451]**

E. Mosca, Institute of Physiology, University of Cagliari, I-09100 Cagliari, Italy **[13]**

Dick Mossberg, Department of Psychiatry, Karolinska Institute, St. Göran's Hospital, S-112 81 Stockholm, Sweden **[153]**

Arie H. Mulder, Department of Pharmacology, Free University, Faculty of Medicine, NL-1081 BT Amsterdam, The Netherlands **[47]**

Viktor Mutt, Departments of Histology, Pharmacology, and Biochemistry, Karolinska Institute, S-10401 Stockholm, Sweden **[231]**

Charles B. Nemeroff, Department of Psychiatry, University of North Carolina, School of Medicine, Chapel Hill, NC 27514 **[199]**

R.A. North, Neuropharmacology Laboratory, Massachusetts Institute of Technology, Cambridge, MA 02139 **[207]**

Johan Offermeier, Department of Pharmacology, Potchefstroom University, Potchefstroom 2520, South Africa 4 **[309]**

S.-O. Ögren, Astra Läkemedel AB, Department of Pharmacology, S-151 85 Södertälje, Sweden **[285]**

Lars Olson, Department of Histology, Karolinska Institute, S-10401 Stockholm, Sweden **[219,333]**

José M. Palacios, Preclinical Research, Sandoz Ltd., CH-4002 Basel, Switzerland **[73]**

M. Palkovits, Laboratory of Cell Biology, National Institute of Mental Health, Bethesda, MD 20205 **[419]**

Michael R. Palmer, Department of Pharmacology, University of Colorado Health Sciences Center, Denver, CO 80262 **[219]**

Jorge Pérez-Cruet, Psychiatry Service, Veterans Administration Hospital and the University of Puerto Rico School of Medicine, San Juan 00936, Puerto Rico **[271]**

Q. Pittman, Division of Pharmacology and Therapeutics, University of Calgary, Calgary, Alberta, Canada T2N 1N4 **[159]**

L.A. Pohorecky, Rutgers University, Center of Alcohol Studies, New Brunswick, NJ 08903 **[169]**

Arthur J. Prange, Jr., Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, NC 27514 **[199]**

P. Protais, U.E.R. de Médecine et Pharmacie, F-76800 St. Etienne-du-Rouvray, France **[59]**

L. Proulx, MRC Group in Molecular Endocrinology, Le Centre Hospitalier de l'Université Laval, Québec G1V 4G2, Canada **[409]**

D. Eugene Redmond, Jr., Neurobehavior Laboratory, Yale University Medical School, New Haven, CT 06510 **[477]**

M. Reibaud, Groupe NB, INSERM U. 114, Collège de France, F-75231 Paris cedex 5, France **[103]**

T.D. Reisine, Pharmacology Lab, Clinical Science, NIMH, Bethesda, MD 20205 **[419]**

R.A. Rius, Department of Pharmacology and Pharmacognosy, University of Milan, I-20129 Milano, Italy **[141]**

T.W. Robbins, Department of Experimental Psychology and Anatomy, University of Cambridge, Cambridge CB2 3EB, UK **[473]**

J. Rogers, Department of Neurology, University of Massachusetts Medical Center, Worcester, MA 01605 **[159]**

S.B. Ross, Department of Pharmacology, Astra Läkemedel AB, S-151 85 Södertälje, Sweden **[285]**

Z.L. Rossetti, Institute of Pharmacology, University of Cagliari, I-09100 Cagliari, Italy **[13]**

Robert H. Roth, Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06510 **[3,25,37,43]**

Helen E. Savaki, INSERM U 114, Collège de France, F-75005 Paris, France **[113]**

Anton N.M. Schoffelmeer, Department of Pharmacology, Free University, 1081 BT Amsterdam, The Netherlands **[47]**

Wolfram Schultz, Institute of Physiology, University of Fribourg, CH-1700 Fribourg, Switzerland **[401]**

Marianne Schultzberg, Department of Histology, Karolinska Institute, S-104 01 Stockholm, Sweden **[239]**

J.-C. Schwartz, Unité de Neurobiologie, Centre Paul Broca de l'INSERM, F-75014 Paris, France **[59]**

Michèle Sebben-Perez, Unité de Neuroendocrinologie, Centre Paul Broca de l'INSERM, F-75014 Paris, France **[93]**

Lewis S. Seiden, The University of Chicago, Department of Pharmacological and Physiological Sciences, Chicago, IL 60637 **[275]**

Åke Seiger, Department of Histology, Karolinska Institute, S-104 01 Stockholm, Sweden **[219]**

William J. Shoemaker, The Salk Institute, San Diego, CA 92138 **[137]**

G.R. Siggins, The Salk Institute, San Diego, CA 92138 **[131,159]**

H. Simon, Laboratoire de Neurobiologie des Comportements, Université de Bordeaux II, F-33076 Bordeaux cedex, France **[293]**

P. Sokoloff, Unité de Neurobiologie, Centre Paul Broca de l'INSERM, F-75014 Paris, France **[59]**

P.F. Spano, Department of Pharmacology and Pharmacognosy, University of Milan, 20129 Milano, Italy **[141]**

Klaus Starke, Institute of Pharmacology, Universität Freiburg, D-7800 Freiburg, FRG **[5]**

D. Staunton, 293 Grover Road, St. Louis, MO 63125 **[159]**

L. Steardo, Experimental Therapeutics Branch, National Institute of Neurological and Communicative Disorders and Stroke, Bethesda, MD 20205 **[343]**

George F. Steinfels, Department of Psychology, Princeton University, Princeton, NJ 08544 **[393]**

Johannes C. Stoof, Department of Neurology, Free University, 1081 BT Amsterdam, The Netherlands **[47]**

Robert E. Strecker, Department of Psychology, Princeton University, Princeton, NJ 08544 **[393]**

Edward M. Stricker, Department of Psychology, University of Pittsburgh, Pittsburgh, PA 15260 **[259]**

J.M. Studler, Groupe NB, INSERM U. 114, Collège de France, F-75231 Paris cedex 5, France **[103]**

B. Tabakoff, Department of Physiology and Biophysics, University of Illinois at Chicago Health Sciences Center, Westside Veterans Administration Medical Center, Chicago, IL 60612 **[145]**

J.P. Tassin, Groupe NB, INSERM U.114, Collège de France, F-75231, Paris cedex 5, France **[103]**

Kazuhiko Tatemoto, Departments of Histology, Pharmacology, and Biochemistry, Karolinska Institute, S-104 01 Stockholm, Sweden **[179,231]**

L. Terenius, Department of Pharmacology, Uppsala University, S-75123 Uppsala, Sweden **[179,231]**

Elvar Theodorsson-Norheim, Department of Pharmacology, Uppsala University, S-75123 Uppsala, Sweden **[231]**

Ulla Thornström, Department of Medical Pharmacology, Box 573, Biomedicum, S-751 23 Uppsala, Sweden **[19]**

M. Trabucchi, Department of Pharmacology and Pharmacognosy, University of Milan, I-20129 Milano, Italy **[141]**

Peter Valverius, Department of Psychiatry, Karolinska Institute, St. Göran's Hospital, S-112 81 Stockholm, Sweden **[153]**

Dicky Van Heuven-Nolsen, Rudolf Magnus Institute for Pharmacology, University of Utrecht, NL-3521 GD Utrecht, The Netherlands **[213]**

M. Vasse, Laboratoire de Pharmacodynamie et Physiologie, U.E.R. de Médecine et Pharmacie, B.P. 97, F-76800 St. Etienne-du-Rouvray, France **[59]**

Dirk H.G. Versteeg, R. Magnus Institute, University of Utrecht, Vondellan 6, NL-3521 GD Utrecht, The Netherlands **[213]**

M.M. Voigt, Department of Pharmacology, St. Louis School of Medicine, St. Louis, MO 63104 **[359]**

J.R. Walters, Experimental Therapeutics Branch, National Institute of Neurological and Communicative Disorders and Stroke, Bethesda, MD 20205 **[343]**

R.Y. Wang, Department of Pharmacology, St. Louis University School of Medicine, St. Louis, MO 63104 **[359]**

B.L. Waszczak, National Institute of Neurological and Communicative Disorders and Stroke, NIH, Bethesda, MD 20205 **[343]**

Johan Wemer, Department of Pharmacology, Free University, NL-1081 BT Amsterdam, The Netherlands **[47]**

C.G. Wermuth, Laboratoire de Pharmacochimie Moléculaire, Centre de Neurochimie, F-67000 Strasbourg, France **[59]**

F.J. White, Department of Pharmacology, St. Louis School of Medicine, St. Louis, MO 63104 **[359]**

J.T. Williams, Neuropharmacology Laboratory, Massachusetts Institute of Technology, Cambridge, MA 02139 **[207]**

Marina E. Wolf, Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06510 **[25]**

G.N. Woodruff, Neuroscience Research Center, Merck Sharp & Dohme Ltd., Hoddesdon, Herts EN11 9BU, UK **[403]**

Suzanne M. Wuerthele, Department of Pharmacology, University of Colorado Health Sciences Center, Denver, CO 80262 **[333]**

W. Wuttke, Department of Reproductive Biology, German Primate Center, D-3400 Göttingen, FRG **[463]**

Richard Wyatt, Department of Health and Human Services, St. Elizabeth's Hospital, Washington, DC 20032 **[333]**

Michael J. Zigmond, Department of Biological Sciences, University of Pittsburgh, Pittsburgh, PA 15260 **[259]**

Isabella Zini, Department of Human Physiology, University of Modena, I-41100 Modena, Italy **[191]**

Contents of Parts A and C

Part A: Basic and Peripheral Mechanisms

Part C: Neuropharmacology and Central Nervous System—Therapeutic Aspects

Preface

The proceedings of the Fifth International Catecholamine Symposium (5 CA), which was held in Göteborg, Sweden (June 1983), are being published as a set of three volumes, which are also available as individual, independent volumes: A. Basic and Peripheral Mechanisms; B. Neuropharmacology and Central Nervous System—Theoretical Aspects; C. Neuropharmacology and Central Nervous System—Therapeutic Aspects. There are certain redundancies: complete Table of Contents, Index, Abbreviations are included in each volume. Although each volume is an entity on its own, owners of one volume will, hopefully, see intriguing entries in the Table of Contents or the Subject Index which will impel them to buy the other volumes. The list of committee members appears in Part A only, and the list of conference participants in Part C only.

Earl Usdin

P.S.*

During the printing of this volume, we were reached by the message that our colleague and dear friend, Earl Usdin, died on May 26, 1984. He had been ill for some time, and his death was not unexpected. Nevertheless, we are struck by sorrow and a feeling of deep loss. The scientific community has lost a highly talented and dedicated worker with an extraordinary command of the English language. Earl Usdin was, with his warm-hearted, generous personality and unique talent for organization, the catalyst of so many international scientific meetings in the field of neuropsychopharmacology, including the CA meetings. He mastered the editing of an impressive number of volumes, more than sixty, thus collecting essential new knowledge in comprehensive units.

Earl Usdin's activities were characterized by dedication, excellence, and a deep sense of humor. He guided the organization of 5 CA in a way which created feelings of friendship, professional admiration, and, now, a sense of loss in our minds. We regret that he was not given the opportunity to pursue his important work as organizer of scientific meetings and editor of books, now that his new position at Irvine had evidently created excellent conditions for this sort of work which was so close to his heart and which he mastered so well. We likewise regret that he was not given the satisfaction of seeing the present three volumes of the 5 CA proceedings, to which he had devoted so much effort.

Earl Usdin has left the catecholamine field, but his spirit will remain with us. All his friends in neuropsychopharmacology will cherish his memory.

Arvid Carlsson
Annica Dahlström
Jörgen Engel

*We are grateful to Alan R. Liss, Inc., for stopping the presses to enable the inclusion of this post script.

Abbreviations

AA = ascorbic acid *or* Alko alcohol (rats)
AADC = (aromatic) amino acid decarboxylase
AC = adenylate cyclase
ACh = acetylcholine
AChE = acetylcholinesterase
ACSF = artificial CSF
ACTH = adrenocorticotrop(h)in
ADDPS = acute dyskinetic, dystonic, parkinsonism syndrome
ADH = antidiuretic hormone
ADP = adenosine diphosphate
(6,7)ADTN = 2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene
AHP = after-hyperpolarization
AIMS = Abnormal Involuntary Movement Scale
Alko = Finnish State Alcohol Monopoly
AMI = amitriptyline
AMP = adenosine monophosphate
AMPH = amphetamine
AMPT = α-methyl-*p*-tyrosine
ANA = Alko nonalcohol (rats)
ANOVA = analysis of variance
ANT = alcohol nontolerant (strain)
4-AP = 4-aminopyridine
APDQ = 4-amino-6,7-dimethoxy-2]4′-(5″(3‴-iodo-4‴-azidophenyl) pentanoyl]-1′-piperazinyl) quinazoline
APO = apomorphine
APP = avian pancreatic polypeptide
App(NH)p = adenosylimidophosphate
AT = angiotensin *or* alcohol tolerant (strain)
ATP = adenosine triphosphate
ATPase = adenosine triphosphatase
AVP = (arginine)vasopressin
AVP-A = [$Asu^{1,6}Arg^{8}$]vasopressin

BAC = blood alcohol concentration(s)
BAT = brown adipose tissue
BBB = blood-brain barrier
BH_4 = tetrahydrobiopterin
BiP = bipolar
BLI = bombesin-like immunoreactivity
BMB = bombesin
BP = blood pressure
BPI = bipolar I
BPII = bipolar II
BPP = bovine pancreatic polypeptide
BPRS = Brief Psychiatric Rating Scale
BRO = bromocriptine
BSA = bovine serum albumin
BZD = benzodiazepine(s)

CA = catecholamine(s)
Ca = calcium (ion)
CaM = calmodulin
cAMP = cyclic AMP
CAR = conditioned avoidance response
CAT = computer axial tomography
CBZ = carbamazepine
CCK = cholecystokinin
Cd = cadmium (ions)
cDNA = complementary DNA
cGMP = cyclic GMP
ChAT = choline acetyltransferase
ChE = cholinesterase
CHF = congestive heart failure
CLG = cyclo(leucine-glycine)
CM = conditioned medium (by heart cells)
CNS = central nervous system
COMT = catecholamine O-methyltransferase
ConA = concanavallin A
CPRS = Comprehensive Psychopathological Rating Scale
CPZ = chlorpromazine